Results 41 to 50 of about 410,888 (293)
Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
Journal of Market Access & Health Policy, 2020 Background: Limited previous research and guidelines on the design of economic evaluation for biosimilars have led to unresolved methodological questions on how to assess biosimilars.
Evelien Moorkens +4 more
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective This systematic review aimed to assess the diagnostic accuracy of algorithms used to identify rheumatoid arthritis and juvenile idiopathic arthritis in electronic health records. Methods We searched Medline, Embase, and Cochrane Central Register for Controlled Trials databases and included studies that validated case definitions against a ...
Constanza Saka‐Herrán +10 more
wiley +1 more source
Pricing of orphan drugs in oncology and rare diseases
Journal of Market Access & Health Policy, 2020 Objective: The objective of this paper is to determine an upper price limit for an orphan drug by taken a broader perspective and, including also other monetary and non-monetary values for the society.
Mark Nuijten, Stefano Capri
doaj +1 more source
The relationship of drug reimbursement with the price and the quality of pharmaceutical innovations [PDF]
, 2005 This paper studies the strategic interaction between pharmaceutical firms' pricing decisions and government agencies' reimbursement decisions which discriminate between patients by giving reimbursement rights to patients for whom the drug is most ...
García-Alonso, M. D. C. +1 more
core
Arthritis Care &Research, Accepted Article.Objective To support high‐quality, patient‐centered care for systemic lupus erythematosus (SLE), the American College of Rheumatology (ACR) developed evidence‐based measures incorporating clinical and patient‐reported outcomes measures (PROMs). Using the Consolidated Framework for Implementation Research (CFIR), we conducted semi‐structured interviews ...
Catherine Nasrallah +13 more
wiley +1 more source
International Journal for Equity in Health, 2019 Background Out-of-pocket (OOP) payments can constitute a major barrier for affordable and equitable access to essential medicines. Household surveys in Kyrgyzstan pointed to a perceived growth in OOP payments for outpatient medicines, including those ...
Sabine Vogler +3 more
doaj +1 more source
A Case Study of an Agency\u27s Three Family Preservation Contracts [PDF]
, 2002 This article presents a case study of a nonprofit child welfare agency that delivered family preservation services under three different purchase-of-service (POS) contracts.
Ezell, Mark
core +1 more source
Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications [PDF]
, 2019 © 2019 Salek, Lussier Hoskyn, Johns, Allen and Sehgal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).This analysis follows our recent study showing that Canadian public reimbursement delays
Adcock +15 more
core +3 more sources
Chemically Doped Conductive Polymers for Wearable Health Monitoring
Advanced Materials Technologies, EarlyView.Among conductive polymers, poly(3,4‐ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS), polyaniline (PANI), and polypyrrole (PPy) are the most studied and applied. Chemical doping significantly boosts intrinsic conductivity and mechanical robustness.
Mengdi Zuo +5 more
wiley +1 more source
Health Economics Review, 2018 Background Regulatory approval and reimbursement decisions are necessary if new drugs are to become accessible in a timely manner. However, the process of regulatory approval and the establishment of reimbursement decisions varies across countries.
Kyung-Bok Son
doaj +1 more source